Curriculum Vitae

Pharmacologist, Central Research Center of Eisai Co.,Ltd, Tsukuba, Japan (4/1984–3/1986); Associate Scientist, Dept of Pharmacol, Kumamoto Univ (4/86–9/91); Assistant Prof. (10/91-5/96); Post Doc., Dept of Anatomy and Cardiovascular Inst., Sch. of Medicine, UCSF, San Francisco, USA (7/93-4/95); Associate Prof., Dept of Pharmacol. Kumamoto Univ. (6/96-3/01); Prof., Dept of Mol Med (4/01-3/23); Vice Dean, Grad Sch of Pharmaceu Sci, (4/13-3/15); Dean (4/15-3/21); Vice President, Kumamoto Univ. (4/21-3/23); Prof. Emeritus & Adjunct Prof., Kumamoto Univ. (4/23-present); CSO C-HAS plus, Co.,Ltd. (4/22-present); CEO GALTS Pharma, Co.,Ltd. (8/23-present)

Alport Syndrome Foundation Scientific Advisory Research Network member (present)

Close

Curriculum Vitae

Ph.D. Research areas include pharmacology, protein expression and purification, haematology and immunology; clinical areas include oncology, infectious diseases, endocrinology, inflammation and respiratory. During 35 years in the pharmaceutical industry, he worked for Kyowa Kirin Co., Ltd., Novartis KK, and drug discovery startup companies, contributing to the approval of eight pharmaceutical products ranging from small and medium molecules to genetically modified entities. CEO of MediComazawa Co. Ltd. and Visiting Prof. Kumamoto Univ (current).

Close

Curriculum Vitae

After working in the International Department of the Bank of Japan and studying at Columbia Law School for his master degree, Mr. Sugiyama worked in the Tokyo and New York offices of Davis Polk & Wardwell LLP, focusing on global capital market transactions, M&A transactions, corporate governance, and international business restructuring matters. He then joined Amazon Japan as in-house counsel, leading legal affairs in its operations business and compliance.

Since fall 2020, he has served as an executive officer and an outside board member of Tokyo Stock Exchange-listed companies and advised startups on overseas expansion and business strategies both in Tokyo and Kyushu. He supports corporate and startup overseas subsidiary management, expansion strategies, corporate governance, M&A, business succession, and alliance strategies. Additionally, he is serving a Visiting Professor at Tokai University, leading the establishment of the Agri-Science Open Innovation Center at its Kumamoto Campus as an Executive Advisor to enhance collaboration with local businesses and regional governments.

Close

Curriculum Vitae

After working for Sumitomo Mitsui Banking Corporation and Ernst & Young ShinNihon (now Ernst & Young ShinNihon LLC), where he oversaw accounting audits of global companies and supported the implementation of IFRS, he joined ABeam Consulting. At ABeam, he developed reform concepts for accounting and related operations and facilitated the establishment of shared service centers. In 2017, he joined Prored Partners as a consultant, and then served as the executive officer in charge of the management headquarters. In this role, he was involved in promoting IPO preparations and formulating IR policies and capital strategies after listing. After leaving Prored Partners in 2020, he has primarily worked with unlisted companies, providing IPO preparation support, business reform guidance, and internal control establishment. He has been actively engaged with these companies as a director, advisor, or outsourced expert.

Close

Curriculum Vitae

Ph.D. Specialising in pharmacology, he has knowledge and experience in preclinical research and clinical development (Phase I/II) in cardiovascular, gastrointestinal, central nervous system, haematology, inflammation, immunology and oncology at pharmaceutical companies in Japan and abroad. In terms of management, he has worked as a group leader at Ono, Japan Tobacco and Fujifilm pharmaceuticals, and as a global project leader at Pfizer (UK), where he was involved in drug development, mentoring subordinates and coordinating between departments. He also managed a team of about 40 people as a department head of pharmacokinetics, pharmacodynamics and safety.

Close

About GALTS Pharma

GALTS Pharma, a drug discovery startup company registered on 22 August 2023, means Good for Alport Syndrome and Good for All Three Sides. We have come together with the vision of getting the candidate drug into the hands of patients in the shortest time.

Good for All Three Sides

”Good for all three sides," implies that a particular situation, decision, or outcome is beneficial or advantageous for all parties involved. The phrase "all three sides" refer to three key entities, groups, or individuals affected by a given circumstance. Here's a general breakdown of what it could mean:

  1. Mutual Benefits The interests of the first party are met and satisfied. The second party also gains advantages and positive outcomes. The third party experiences favorable results.
  2. Balanced and Fair The situation is characterized by fairness and equity. The needs and concerns of all three sides are considered and addressed. There is a sense of fairness in the arrangement.
  3. Harmony and Cooperation The interactions between the parties are cooperative and harmonious. Collaboration is encouraged, fostering positive relationships. Conflict and disagreement are minimized, contributing to a positive environment.
  4. Sustainable The benefits are not short-term but contribute to long-term stability. The arrangement is designed to be sustainable, ensuring ongoing positive outcomes for all parties involved.
  5. Win-Win-Win Situation Each party gains something valuable, creating a "win" for everyone. The interests of one party do not come at the expense of the others. It goes beyond a zero-sum game, where one's gain is not necessarily someone else's loss.